These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8096798)

  • 41. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
    King CR; Swain SM; Porter L; Steinberg SM; Lippman ME; Gelmann EP
    Cancer Res; 1989 Aug; 49(15):4185-91. PubMed ID: 2568168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA amplification of the c-myc and c-erbB-1 genes in a human stomach cancer.
    Nomura N; Yamamoto T; Toyoshima K; Ohami H; Akimaru K; Sasaki S; Nakagami Y; Kanauchi H; Shoji T; Hiraoka Y
    Jpn J Cancer Res; 1986 Dec; 77(12):1188-92. PubMed ID: 3102422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
    Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
    Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG; Schelling ME; Hosick HL
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo.
    Bover L; Barrio M; Bravo AI; Slavutsky I; Larripa I; Bolondi A; Ayala M; Mordoh J
    Cell Mol Biol (Noisy-le-grand); 1998 May; 44(3):493-504. PubMed ID: 9620446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.
    Lemoine NR; Staddon S; Dickson C; Barnes DM; Gullick WJ
    Oncogene; 1990 Feb; 5(2):237-9. PubMed ID: 2181382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Oncogenes and anti-oncogenes in breast cancer].
    Birnbaum D; Gaudray P
    Bull Cancer; 1989; 76(7):677-87. PubMed ID: 2573395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc.
    Nass SJ; Dickson RB
    Clin Cancer Res; 1998 Jul; 4(7):1813-22. PubMed ID: 9676860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Wells CA
    Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
    Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2 testing: a review of detection methodologies and their clinical performance.
    Laudadio J; Quigley DI; Tubbs R; Wolff DJ
    Expert Rev Mol Diagn; 2007 Jan; 7(1):53-64. PubMed ID: 17187484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas.
    Pääkkö P; Nuorva K; Kamel D; Soini Y
    Am J Respir Cell Mol Biol; 1992 Sep; 7(3):325-34. PubMed ID: 1355655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
    Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
    J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.